Genetic modifications or deletions of tumor suppressors, such as Trp53, in combination with activating mutations in proto-oncogenes, such as KRas, are a prerequisite to facilitate a tumor-initiating event (Best et al., 2019). This evidence concerns the gene KRAS and neoplasm.